Olema Pharmaceuticals, Inc.(OLMA)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Pending next ranking run
This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
OLMA Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Olema Pharmaceuticals, Inc. (OLMA), a Healthcare sector company. OLMA is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q1 2026), Olema Pharmaceuticals, Inc. reports net income of $-53.1M, free cash flow of $-46.0M. Top institutional holders of OLMA by reported 13-F value include FMR, Paradigm Biocapital Advisors, Bain Capital Life Sciences Investors,, based on the most recent SEC filings. OLMA trades on the Nasdaq exchange and files with the SEC under CIK 1750284. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate OLMA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Olema Pharmaceuticals, Inc. directly from SEC EDGAR.
Net Income
Q1 2026
$-53.1M
Free Cash Flow
Q1 2026
$-46.0M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Net Income
-25.5% YoYOperating Income
-25.6% YoYEPS (Diluted)
+15.0% YoYTotal Assets
+18.3% YoYOp. Cash Flow
-40.6% YoY| Metric | FY 2025 | FY 2024 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Net Income | $-162.5M -25.5% | $-129.5M -23.6% | $-104.8M -47.4% | $-71.1M -221.4% | $-22.1M -412.5% | $-4.3M |
| Operating Income | $-178.7M -25.6% | $-142.3M -33.0% | $-107.0M -49.7% | $-71.5M -232.1% | $-21.5M -398.0% | $-4.3M |
| EPS (Diluted) | $-1.87 +15.0% | $-2.20 +16.0% | $-2.62 -45.6% | $-1.80 +47.4% | $-3.42 -106.0% | $-1.66 |
| Total Assets | $533.4M +18.3% | $451.0M +109.1% | $215.6M -27.1% | $295.9M -13.6% | $342.7M | — |
| Operating Cash Flow | $-146.7M -40.6% | $-104.4M -27.2% | $-82.1M -61.9% | $-50.7M -155.2% | $-19.9M -544.8% | $-3.1M |
AI Insight: OLMA Ratio Trends
Data is too sparse to assess margins or leverage; available return metrics show deep, persistent losses with no clear improvement trend.
• ROE remained deeply negative across all periods, ranging from -31.7% in Q1 2025 to -69.5% in Q3 2024.
• ROIC oscillated between -36.0% and -75.6% across quarters, reflecting ongoing capital consumption with no sustained recovery.
• OpMargin, NPM, and D/E are entirely absent across all reported periods, limiting analytical depth.
⚠ ROIC deteriorated to -48.3% in Q1 2026 from -41.9% in Q4 2025 — a sequential step-back after modest stabilization.
⚠ Absence of OpMargin and D/E data makes it impossible to assess burn rate trajectory or balance sheet risk.
Get alerted when OLMA's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Olema Pharmaceuticals, Inc. including:
Top Institutional Holders of OLMA
FMR LLC
$154.9M10,386,845 shParadigm Biocapital Advisors LP
$119.6M8,020,576 shBain Capital Life Sciences Investors, LLC
$111.4M7,473,238 shJANUS HENDERSON GROUP PLC
$106.0M7,108,488 shBlackRock, Inc.
$84.3M5,652,135 shBVF INC/IL
$79.0M5,295,893 shSiren, L.L.C.
$70.9M4,756,949 shSTATE STREET CORP
$58.7M3,937,831 shCormorant Asset Management, LP
$58.1M3,900,000 shLogos Global Management LP
$47.8M3,208,875 sh
| Fund | Value | Shares |
|---|---|---|
| FMR LLC | $154.9M | 10,386,845 |
| Paradigm Biocapital Advisors LP | $119.6M | 8,020,576 |
| Bain Capital Life Sciences Investors, LLC | $111.4M | 7,473,238 |
| JANUS HENDERSON GROUP PLC | $106.0M | 7,108,488 |
| BlackRock, Inc. | $84.3M | 5,652,135 |
| BVF INC/IL | $79.0M | 5,295,893 |
| Siren, L.L.C. | $70.9M | 4,756,949 |
| STATE STREET CORP | $58.7M | 3,937,831 |
| Cormorant Asset Management, LP | $58.1M | 3,900,000 |
| Logos Global Management LP | $47.8M | 3,208,875 |
More Healthcare Companies
View all Healthcare →Put OLMA on your watchlist
Track score changes the day Olema Pharmaceuticals, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is OLMA a good stock to buy?
13F Pro's AI-powered analysis of Olema Pharmaceuticals, Inc. (OLMA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for OLMA are available on the OLMA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own OLMA?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling OLMA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Olema Pharmaceuticals, Inc.'s investment landscape.